REVEAL GENOMICS ®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical ...

Vivian Dsena reunites with Rubina Dilaik on Laughter Chefs 2 for a special Holi episode, bringing back the beloved #HaYa duo from Shakti – Astitva Ke Ehsaas Ki. They share nostalgic moments and ...

Sir Keir Starmer has pledged to slash the costs of regulation with an "active government". In a speech, he said politicians had chosen to hide behind quangos and he took aim at a "cottage industry ...

Knowing the HER2 status of ER+/PR+ breast cancer is important to choose the right treatment strategy so patients get the best care. Proliferation rate is the percentage of cancer cells that are ...

The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast cancer who had already tried CDK 4/6 inhibitors ...

Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it ...

It was Trump who decided to end that generational innocence. American voters might not have realized that nuclear proliferation was on the ballot last fall, but here we are. Steve Benen is a ...

Forbes contributors publish independent expert analyses and insights. News and opinion about video games, television, movies and the internet.

Early in the Cold War, following the advent of nuclear weapons, the United States did not intuitively grasp the reasons why nuclear proliferation to its friends would harm its interests. It was only ...

“Proliferation will beget more proliferation,” said the former senior White House official. Yet Trump has also said he wants to reduce global spending on nuclear weapons. Last month, he called ...

HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial is supported by ...